Literature DB >> 16962489

Complete response of bony metastatic bladder urothelial cancer to neoadjuvant chemotherapy and cystectomy.

Fadi N Joudi1, Laila Dahmoush, David M Spector, Badrinath R Konety.   

Abstract

We report on a 38-year-old male diagnosed with biopsy-proven bladder urothelial carcinoma metastatic to the bone, who had a complete response to neoadjuvant chemotherapy consisting of carboplatin and gemcitabine. The final pathology of his radical cystoprostatectomy revealed no residual cancer. The patient continues to be without evidence of disease 2 years postoperatively. This case shows that neoadjuvant chemotherapy with nonstandard regimens can yield responses in patients with bone metastases.

Entities:  

Mesh:

Year:  2006        PMID: 16962489     DOI: 10.1016/j.urolonc.2005.12.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  3 in total

1.  Role of Multimodal Treatment in Urothelial Carcinoma Spinal Metastasis: 15 Patients' Experiences in a Single Center.

Authors:  Tao Wang; Xin Gao; Kun Zhang; Jian Yang; Zheyu Wu; Tielong Liu; Qi Jia; Jianru Xiao
Journal:  Cancer Manag Res       Date:  2020-09-24       Impact factor: 3.989

2.  Long-term survival in bone-predominant metastatic urothelial carcinoma.

Authors:  Jorge D Ramos; Heather H Cheng; Evan Y Yu
Journal:  Clin Genitourin Cancer       Date:  2014-07-23       Impact factor: 2.872

3.  Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Authors:  Andrea Necchi; Gregory R Pond; Sumanta K Pal; Neeraj Agarwal; Daniel W Bowles; Elizabeth R Plimack; Evan Y Yu; Sylvain Ladoire; Jack Baniel; Simon Crabb; Gunter Niegisch; Sandy Srinivas; Dominik R Berthold; Jonathan E Rosenberg; Thomas Powles; Aristotelis Bamias; Lauren C Harshman; Joaquim Bellmunt; Matthew D Galsky
Journal:  Clin Genitourin Cancer       Date:  2017-11-01       Impact factor: 2.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.